Clinical Trials | December 03, 2025
Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Roche says the move marks a step forward in its digital transformation strategy
Subscribe To Our Newsletter & Stay Updated
